BRIDGEBIO PHARMA INC
(NASDAQ: BBIO)

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

30.880

+1.120 (+3.76%)
Range 29.620 - 31.230   (5.44%)
Open -
Previous Close 29.760
Bid Price 13.170
Bid Volume 11
Ask Price 13.170
Ask Volume 10
Volume 1,785,030
Value -
Remark
Delayed prices. Updated at 28 Mar 2024 03:59.
Data powered by
View All Events


Loading Chart...

Please login to view stock data and analysis